Publications by authors named "Isao Fujioka"

Claim this Profile
C
Case Report: Persistent COVID-19 in a fully vaccinated Japanese man being treated with rituximab and epcoritamab for diffuse large B-cell lymphoma.
Masaki Suzuki, Isao Fujioka, Takamitsu Matsushima

Front Med (Lausanne)· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors.
Yuriko Nishiyama-Fujita, Tomonori Nakazato, Noriyoshi Iriyama, Michihide Tokuhira, Maho Ishikawa, Isao Fujioka

Ann Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bosutinib-induced late-onset severe liver injury preceded by eosinophilia.
Naoki Watanabe, Tomoiku Takaku, Isao Fujioka, Shun Tsuchiya, Miki Ando

Ann Hematol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Microgranular-type acute promyelocytic leukemia with weak myeloperoxidase staining: difficulty of morphological diagnosis].
Hiroka Matsuda, Kyohei Misawa, Tomonori Ochiai, Isao Fujioka, Hisayo Iwasaki

Rinsho Ketsueki· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort.
Eriko Sato, Noriyoshi Iriyama, Michihide Tokuhira, Tomoiku Takaku, Maho Ishikawa, Isao Fujioka

Cancer Med· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential role for second‑generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia harboring additional clonal chromosome abnormalities: A retrospective CML Cooperative Study Group analysis.
Maho Ishikawa, Noriyoshi Iriyama, Michihide Tokuhira, Tomoiku Takaku, Eriko Sato, Isao Fujioka

Oncol Rep· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Smoking influences the outcomes of patients receiving tyrosine kinase inhibitors for chronic myeloid leukemia in the chronic phase: A retrospective analysis.
Noriyoshi Iriyama, Michihide Tokuhira, Eriko Sato, Kei-Ji Sugimoto, Tomoiku Takaku, Isao Fujioka

Hematol Oncol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database.
Isao Fujioka, Tomoiku Takaku, Noriyoshi Iriyama, Michihide Tokuhira, Yuta Kimura

Ann Hematol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis.
Noriyoshi Iriyama, Kei-Ji Sugimoto, Eriko Sato, Tomoiku Takaku, Michihide Tokuhira, Isao Fujioka

Med Oncol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score.
Eriko Sato, Noriyoshi Iriyama, Michihide Tokuhira, Tomoiku Takaku, Maho Ishikawa, Isao Fujioka

Leuk Lymphoma· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors.
Tomonori Nakazato, Noriyoshi Iriyama, Michihide Tokuhira, Maho Ishikawa, Eriko Sato, Isao Fujioka

Med Oncol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Chronic myeloid leukemia complicated by pulmonary hypertension during dasatinib therapy: a single-center retrospective study].
Yoko Edahiro, Tomoiku Takaku, Hakuoh Konishi, Yutaka Tsukune, Isao Fujioka

Rinsho Ketsueki· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase.
Michihide Tokuhira, Yuta Kimura, Keiji Sugimoto, Tomonori Nakazato, Maho Ishikawa, Isao Fujioka

Med Oncol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study Group.
Noriyoshi Iriyama, Michihide Tokuhira, Tomoiku Takaku, Eriko Sato, Maho Ishikawa, Isao Fujioka

Leuk Res· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Primary pulmonary Hodgkin lymphoma diagnosed by CT-guided percutaneous biopsy].
Naoki Watanabe, Isao Fujioka, Yasuo Aota, Jun Ando, Masaru Tanaka

Rinsho Ketsueki· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis